Cargando…

Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis

Heparin, a mixture of sulfated polymorphic polysaccharides (glycosaminoglycan) chains of variable lengths and weights and a natural anticoagulant, is widely used in medical practice to prevent intravascular blood coagulation. Heparin has demonstrated antithrombotic and anti-inflammatory activity, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabré, Francesc, Camacho, Jairo A, Rodríguez-Garcés, Carlos A, Breier, Débora V, Ballarin, Martín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658445/
https://www.ncbi.nlm.nih.gov/pubmed/38022089
http://dx.doi.org/10.7759/cureus.47418
_version_ 1785137418535436288
author Cabré, Francesc
Camacho, Jairo A
Rodríguez-Garcés, Carlos A
Breier, Débora V
Ballarin, Martín
author_facet Cabré, Francesc
Camacho, Jairo A
Rodríguez-Garcés, Carlos A
Breier, Débora V
Ballarin, Martín
author_sort Cabré, Francesc
collection PubMed
description Heparin, a mixture of sulfated polymorphic polysaccharides (glycosaminoglycan) chains of variable lengths and weights and a natural anticoagulant, is widely used in medical practice to prevent intravascular blood coagulation. Heparin has demonstrated antithrombotic and anti-inflammatory activity, and it is mostly administered systemically (intravenously or subcutaneously) for primary or secondary prevention of venous thromboembolism after surgical interventions, or immobilized patients, or on short-term antithrombotic therapy of patients with atrial fibrillation who must undergo treatment. However, since systemic administration of heparin could be, in certain cases, linked to an increased risk of bleeding, topical heparin is widely used for the prevention and treatment of local symptoms of peripheral vascular disorders, such as venous insufficiency, varicose veins, or superficial thrombophlebitis. This review summarizes the main safety and efficacy characteristics of the topical formulation of Heparin in Gel form (1000 International Units of Heparin/g Gel) currently in use, which has demonstrated an excellent efficacy and tolerability profile in reducing signs and symptoms of peripheral vascular disease, e.g., varicose syndromes and their complications, phlebothrombosis, thrombophlebitis, superficial periphlebitis, varicose ulcers, for post-operative varicophlebitis, sequelae of saphenectomy, for traumas and contusions, local edemas and infiltrates, subcutaneous hematoma and for traumatic affections of musculotendinous and capsuloligamentous apparatuses.
format Online
Article
Text
id pubmed-10658445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106584452023-10-21 Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis Cabré, Francesc Camacho, Jairo A Rodríguez-Garcés, Carlos A Breier, Débora V Ballarin, Martín Cureus Other Heparin, a mixture of sulfated polymorphic polysaccharides (glycosaminoglycan) chains of variable lengths and weights and a natural anticoagulant, is widely used in medical practice to prevent intravascular blood coagulation. Heparin has demonstrated antithrombotic and anti-inflammatory activity, and it is mostly administered systemically (intravenously or subcutaneously) for primary or secondary prevention of venous thromboembolism after surgical interventions, or immobilized patients, or on short-term antithrombotic therapy of patients with atrial fibrillation who must undergo treatment. However, since systemic administration of heparin could be, in certain cases, linked to an increased risk of bleeding, topical heparin is widely used for the prevention and treatment of local symptoms of peripheral vascular disorders, such as venous insufficiency, varicose veins, or superficial thrombophlebitis. This review summarizes the main safety and efficacy characteristics of the topical formulation of Heparin in Gel form (1000 International Units of Heparin/g Gel) currently in use, which has demonstrated an excellent efficacy and tolerability profile in reducing signs and symptoms of peripheral vascular disease, e.g., varicose syndromes and their complications, phlebothrombosis, thrombophlebitis, superficial periphlebitis, varicose ulcers, for post-operative varicophlebitis, sequelae of saphenectomy, for traumas and contusions, local edemas and infiltrates, subcutaneous hematoma and for traumatic affections of musculotendinous and capsuloligamentous apparatuses. Cureus 2023-10-21 /pmc/articles/PMC10658445/ /pubmed/38022089 http://dx.doi.org/10.7759/cureus.47418 Text en Copyright © 2023, Cabré et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Other
Cabré, Francesc
Camacho, Jairo A
Rodríguez-Garcés, Carlos A
Breier, Débora V
Ballarin, Martín
Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title_full Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title_fullStr Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title_full_unstemmed Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title_short Review of Topical Sodium Heparin 1000 IU/g Gel in Symptomatic Uncomplicated Superficial Thrombophlebitis
title_sort review of topical sodium heparin 1000 iu/g gel in symptomatic uncomplicated superficial thrombophlebitis
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658445/
https://www.ncbi.nlm.nih.gov/pubmed/38022089
http://dx.doi.org/10.7759/cureus.47418
work_keys_str_mv AT cabrefrancesc reviewoftopicalsodiumheparin1000iuggelinsymptomaticuncomplicatedsuperficialthrombophlebitis
AT camachojairoa reviewoftopicalsodiumheparin1000iuggelinsymptomaticuncomplicatedsuperficialthrombophlebitis
AT rodriguezgarcescarlosa reviewoftopicalsodiumheparin1000iuggelinsymptomaticuncomplicatedsuperficialthrombophlebitis
AT breierdeborav reviewoftopicalsodiumheparin1000iuggelinsymptomaticuncomplicatedsuperficialthrombophlebitis
AT ballarinmartin reviewoftopicalsodiumheparin1000iuggelinsymptomaticuncomplicatedsuperficialthrombophlebitis